SciBase publishes the Annual report for 2015

SciBase hereby announces that the Annual report for 2015 is available at the
Company’s website www.scibase.com.
A pdf-version of the annual report is enclosed to this press-release.

A printed version of the Annual report will only be distributed to shareholders
who actively request a printed copy.

For more information, please contact:

Michael Colérus, CFO
Tel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com

SciBase Holding AB is required to disclose the information provided herein
pursuant to the Financial Instruments Trading Act. The information was submitted
for publication at 08:00 am on April 25, 2016.

About Skin Cancer

Skin cancer is one of the most common cancers in the world, accounting for
nearly half of all cancers. It has been estimated that nearly half of all
Americans who live to age 65 will develop skin cancer at least once. Malignant
melanoma is the most fatal form of skin cancer causing the majority (75%) of
deaths related to skin cancer. Worldwide, doctors diagnose about 230,000 new
cases of melanoma yearly.

About SciBase and Nevisense

SciBase AB is a Swedish medical technology company, headquartered in Stockholm
that has developed a unique point-of-care device for the accurate detection of
malignant melanoma. Its product, Nevisense, helps doctors to detect malignant
melanoma, the most dangerous type of skin cancer. SciBase was founded by Stig
Ollmar, Associate Professor at The Karolinska Institute in Stockholm, Sweden.
Nevisense is based on substantial research and has achieved excellent results in
the largest clinical study ever conducted on the detection of malignant
melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia, and
is awaiting FDA clearance in the United States. Nevisense is based on a method
called Electrical Impedance Spectroscopy (EIS), which uses the varying
electrical properties of human tissue to categorize cellular structures and
thereby detect malignancies. SciBase is listed on Nasdaq First North (“SCIB”).
Avanza is the certified advisor. Further information is available on
www.scibase.com.